PRN.TO
Profound Medical Corp. [PRN.TO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
PRN.TO Stock Summary
Top PRN.TO Correlated Resources
PRN.TO
Top 10 Correlated ETFs
PRN.TO
Top 10 Correlated Stocks
PRN.TO
In the News
PRN.TO Financial details
Company Rating
-
Market Cap
268.23M
Income
-28.57M
Revenue
7.2M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
131
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-5.37
Forward P/E
-
PEG
1.65
P/S
24.15
P/B
4.06
P/C
-
P/FCF
-7.11
Quick Ratio
7.76
Current Ratio
9.32
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.93
EPS next Y
-
EPS next Q
-
EPS this Y
-2.17%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-0.58%
Revenue last 5Y
11.21%
Revenue Q/Q
16.26%
EPS Q/Q
-
-
-
-
-
SMA20
-26.06%
SMA50
-27.2%
SMA100
-41.19%
Inst Own
-
Inst Trans
-
ROA
-58%
ROE
-64%
ROC
-0.29%
Gross Margin
60%
Oper. Margin
-206%
Profit Margin
-453%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9.55-20.44
52W High
-65.35%
52W Low
-23%
RSI
41.39
Rel Volume
1.48
Avg Volume
4.61K
Volume
6.8K
Perf Week
8.11%
Perf Month
-28.34%
Perf Quarter
-38.13%
Perf Half Y
-33.62%
-
-
-
-
Beta
0.794
-
-
Volatility
0.14%, 1.28%
Prev Close
2.67%
Price
6.93
Change
9.65%
Company Profile
- Volume Average 4.61K
- Market Capitalization 268.23M
- Employee 131
- CEO Dr. Arun Swarup Menawat MBA, Ph.D.
- Headquarters Mississauga,ON,CA
- IPO Date 2018-07-10
-
Website
https://www.profoundmedical.com 
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
